Annual Cash & Cash Equivalents
$174.96 M
+$47.85 M+37.65%
December 31, 2024
Summary
- As of March 10, 2025, DNLI annual cash & cash equivalents is $174.96 million, with the most recent change of +$47.85 million (+37.65%) on December 31, 2024.
- During the last 3 years, DNLI annual cash & cash equivalents has fallen by -$118.52 million (-40.38%).
- DNLI annual cash & cash equivalents is now -65.50% below its all-time high of $507.14 million, reached on December 31, 2020.
Performance
DNLI Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$174.96 M
+$84.32 M+93.04%
December 31, 2024
Summary
- As of March 10, 2025, DNLI quarterly cash and cash equivalents is $174.96 million, with the most recent change of +$84.32 million (+93.04%) on December 31, 2024.
- Over the past year, DNLI quarterly cash and cash equivalents has stayed the same.
- DNLI quarterly cash and cash equivalents is now -65.50% below its all-time high of $507.14 million, reached on December 31, 2020.
Performance
DNLI Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
DNLI Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +37.6% | 0.0% |
| 3 y3 years | -40.4% | 0.0% |
| 5 y5 years | +120.2% | 0.0% |
DNLI Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -40.4% | +37.6% | -40.4% | +188.8% |
| 5 y | 5-year | -65.5% | +120.2% | -65.5% | +188.8% |
| alltime | all time | -65.5% | +469.2% | -65.5% | +428.8% |
Denali Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $174.96 M(+37.6%) | $174.96 M(+93.0%) |
| Sep 2024 | - | $90.64 M(+21.4%) |
| Jun 2024 | - | $74.68 M(+23.3%) |
| Mar 2024 | - | $60.57 M(-52.3%) |
| Dec 2023 | $127.11 M(-41.7%) | $127.11 M(-14.1%) |
| Sep 2023 | - | $148.01 M(+12.2%) |
| Jun 2023 | - | $131.97 M(+93.7%) |
| Mar 2023 | - | $68.13 M(-68.8%) |
| Dec 2022 | $218.04 M(-25.7%) | $218.04 M(+83.8%) |
| Sep 2022 | - | $118.61 M(-23.5%) |
| Jun 2022 | - | $155.09 M(+47.8%) |
| Mar 2022 | - | $104.95 M(-64.2%) |
| Dec 2021 | $293.48 M(-42.1%) | $293.48 M(-25.6%) |
| Sep 2021 | - | $394.55 M(-18.8%) |
| Jun 2021 | - | $485.68 M(+11.6%) |
| Mar 2021 | - | $435.32 M(-14.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2020 | $507.14 M(+538.3%) | $507.14 M(+44.5%) |
| Sep 2020 | - | $351.05 M(+155.9%) |
| Jun 2020 | - | $137.18 M(-33.9%) |
| Mar 2020 | - | $207.54 M(+161.2%) |
| Dec 2019 | $79.45 M(+3.0%) | $79.45 M(-3.9%) |
| Sep 2019 | - | $82.67 M(+31.4%) |
| Jun 2019 | - | $62.94 M(+58.7%) |
| Mar 2019 | - | $39.66 M(-48.6%) |
| Dec 2018 | $77.12 M(-64.7%) | $77.12 M(+76.7%) |
| Sep 2018 | - | $43.65 M(+31.9%) |
| Jun 2018 | - | $33.09 M(-24.8%) |
| Mar 2018 | - | $44.00 M(-79.9%) |
| Dec 2017 | $218.38 M(+448.0%) | $218.38 M(+502.1%) |
| Sep 2017 | - | $36.27 M(-9.0%) |
| Dec 2016 | $39.85 M(+29.6%) | $39.85 M |
| Dec 2015 | $30.74 M | - |
FAQ
- What is Denali Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Denali Therapeutics?
- What is Denali Therapeutics annual cash & cash equivalents year-on-year change?
- What is Denali Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Denali Therapeutics?
- What is Denali Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Denali Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of DNLI is $174.96 M
What is the all time high annual cash & cash equivalents for Denali Therapeutics?
Denali Therapeutics all-time high annual cash & cash equivalents is $507.14 M
What is Denali Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, DNLI annual cash & cash equivalents has changed by +$47.85 M (+37.65%)
What is Denali Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of DNLI is $174.96 M
What is the all time high quarterly cash and cash equivalents for Denali Therapeutics?
Denali Therapeutics all-time high quarterly cash and cash equivalents is $507.14 M
What is Denali Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, DNLI quarterly cash and cash equivalents has changed by $0.00 (0.00%)